Abstract
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer morbidity and mortality, and patients are often diagnosed with advanced disease or metastasis at time of diagnosis. Characterizing circulating tumor cell (CTC) behavior may shed light on the disease’s natural history and treatment response. Methods: We used a commercially available, size-based microfluidic purification technology to isolate CTCs from the whole blood of an exploratory prospective cohort of 23 patients receiving systemic therapy for HCC, both prior to treatment and after 6–8 weeks of treatment. CTC concentrations were quantified using on-chip staining with a cocktail of HCC-specific antibodies followed by rare cell image analysis. CTC counts were correlated with standard laboratory and clinical parameters. Results: Our assay’s sensitivity was higher than previously published. CTC counts did not correlate with disease stage or on-treatment survival. Pre-treatment CTC counts were inversely related to serum alpha-fetoprotein (AFP) levels and were not correlated with circulating tumor DNA quantitative metrics or genomic subsets. On-treatment increase in CTC counts showed a non-significant trend toward improved survival. Conclusions: Serial CTC enumeration on therapy may serve as a novel liquid biopsy approach that complements the data yielded by conventional biomarkers like AFP and ctDNA. Future work will better define how deeper characterization of CTC dynamics and expression profiling can contribute to biomarker development.